colorectal disease with surgical indication (both benign and malignant)
Conditions
Interventions
Patients are given intravenous drip infusion of Cefazolin 1 g and Metronidazole 500 mg as intraoperative antibiotic prophylaxis. Blood (about 2 ml), ascites (about 2 ml), subcutaneous fat (about 4 mm
Sponsors
Department of Infectious Diseases, Hiroshima University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ?Patients scheduled for elective colorectal surgery(limited to open surgery cases) ?Inpatients over 20 years old who agree to participate in this study, regardless of gender ?Patients who can give written informed consent to participate in this study
Exclusion criteria
Exclusion criteria: ?Emergency surgical patient ?Patients requiring extensive small intestine resection ?Patients requiring excision of other organs ?Patients with complications leading to a decrease in liver function ?Patients with a history of allergies to Cefazolin or Metronidazole ?Combined use of Cefazolin or Metronidazole caution drug ?Patients who are pregnant or nursing ?Patients with organic diseases in the brain and spinal cord ?Patients judged inappropriate for this study by the researcher
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters (Cmax, AUC, t1 / 2, tmax) of Metronidazole in blood, ascites and tissue (subcutaneous fat and peritoneum) | — |
Countries
Japan
Contacts
Public ContactHiroyuki Taogoshi
Hiroshima University graduate school Department of Surgery, Applied Life Sciences Institute of Biomedical & Health Sciences
Outcome results
None listed